Stockscreener 앱 받기
25.60
0.19%
-0.05
시간 외 거래:
25.60
전일 마감가:
$25.65
열려 있는:
$25.21
하루 거래량:
1.44M
Relative Volume:
0.37
시가총액:
$4.32B
수익:
$56.99M
순이익/손실:
$-107.23M
주가수익비율:
-31.22
EPS:
-0.8199
순현금흐름:
$-142.55M
1주 성능:
-5.43%
1개월 성능:
-13.66%
6개월 성능:
+98.45%
1년 성능:
+269.94%
1일 변동 폭
$24.75
$25.70
1주일 범위
$24.75
$28.09
52주 변동 폭
$6.25
$34.39
Tango Therapeutics Inc Stock (TNGX) Company Profile
명칭
Tango Therapeutics Inc
전화
(857) 320-4900
주소
201 BROOKLINE AVENUE, BOSTON
Compare TNGX vs VRTX, REGN, ARGX, RVMD, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TNGX
Tango Therapeutics Inc
|
25.60 | 4.31B | 56.99M | -107.23M | -142.55M | -0.8199 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Tango Therapeutics Inc Stock (TNGX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-02 | 개시 | Canaccord Genuity | Buy |
| 2026-02-23 | 개시 | Mizuho | Outperform |
| 2025-11-18 | 개시 | Wolfe Research | Peer Perform |
| 2025-08-19 | 개시 | Piper Sandler | Overweight |
| 2024-07-17 | 개시 | Jefferies | Buy |
| 2024-04-04 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-02-12 | 개시 | Piper Sandler | Overweight |
| 2023-12-08 | 개시 | B. Riley Securities | Buy |
| 2022-10-20 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2021-09-20 | 개시 | SVB Leerink | Outperform |
모두보기
Tango Therapeutics Inc 주식(TNGX)의 최신 뉴스
Walleye Capital LLC Makes New Investment in Tango Therapeutics, Inc. $TNGX - MarketBeat
Tango Therapeutics (NASDAQ:TNGX) Stock Rating Lowered by Wall Street Zen - MarketBeat
Tango Therapeutics (TNGX) investors report 0% beneficial ownership in latest 13G/A - Stock Titan
Tango Therapeutics (TNGX): TCG Crossover and Chen Yu disclose 7% beneficial stake - Stock Titan
Goldman Sachs Group (TNGX) discloses 6.0% beneficial stake in Tango Therapeutics - Stock Titan
Woodline holds 4.0M Tango Therapeutics (TNGX) shares, a 2.5% stake - Stock Titan
Farallon group discloses 16.27M Tango Therapeutics (TNGX) shares and warrants - Stock Titan
Handelsbanken Fonder AB Acquires Shares of 287,900 Tango Therapeutics, Inc. $TNGX - MarketBeat
TNGX Stock Crashes 20% After Reporting $0 Revenue In Q1 — But Analysts Still See Massive Upside - Stocktwits
Tango Therapeutics Insiders Selling US$727k In Stock Relieved As Market Cap Slides To US$4.4b - moomoo.com
Tema ETFs LLC Buys New Holdings in Tango Therapeutics, Inc. $TNGX - MarketBeat
Tango Therapeutics (NASDAQ:TNGX): What Does the Latest Update Mean for Clinical Progress? - Kalkine Media
Tango Therapeutics, Inc. (TNGX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Tango Therapeutics Inc (TNGX) News, Articles, Events & Latest Updates - Stocktwits
Adage Capital discloses 3.44% Tango Therapeutics (TNGX) stake in 13G/A filing - Stock Titan
TNGX Stock Dips 5% as Q2 Earnings Miss Estimates on Higher Expenses - theglobeandmail.com
Wedbush Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Raises Target Price to $39 - moomoo.com
Guggenheim raises Tango Therapeutics stock price target to $35 - Investing.com Nigeria
Guggenheim raises Tango Therapeutics stock price target to $35 By Investing.com - Investing.com Canada
Tango Therapeutics (TNGX) Stock Faces Cash Burn Pressure After Revenue Vanishes - sahmcapital.com
Tango Therapeutics, Inc. Stock 12‑Month Price Target Raised to $44.58, Implies 61% Upside - TradingView
Tango TherapeuticsFiles Prospectus To Sell Up To $400 Million In Common Stock - TradingView
Why is Tango Therapeutics stock sliding today? By Investing.com - Investing.com Canada
Tango Therapeutics Q2 Results: EPS misses estimate, losses widen YoY - scanx.trade
Tango Therapeutics faces earnings test as PRMT5 data fuels rally By Investing.com - Investing.com Australia
Tango Therapeutics faces earnings test as PRMT5 data fuels rally - Investing.com
Tango Therapeutics (NASDAQ:TNGX) Issues Earnings Results - MarketBeat
Form 8K Tango Therapeutics Inc For: 11 August By Investing.com - Investing.com South Africa
Form 8K Tango Therapeutics Inc For: 11 August - Investing.com Nigeria
Tango Therapeutics Q2 Net Loss Widens - marketscreener.com
Tango Therapeutics Reports Q2 Net Loss and $1 Billion Cash Position - quiverquant.com
Tango Therapeutics reports Q2 2026 net loss $55.3M, cash $1.0B as it advances vopimetostat - TradingView
TNGX: 92% response rate in pancreatic cancer drives Phase 3 plans; net loss rises, cash at $1.0B - TradingView
Tango Therapeutics, Inc. Q2 2026: Revenue $0 Net loss $55.34M, EPS ($0.37) — 10-Q Summary - TradingView
Tango Therapeutics (Nasdaq: TNGX) posts higher loss while amassing $1B cash for oncology trials - Stock Titan
Earnings Flash (TNGX) Tango Therapeutics Posts Q2 Loss $0.37 a Share, vs. FactSet Est of $0.32 Loss - marketscreener.com
Tango Therapeutics Q2 net loss widens as expenses rise - TradingView
Earnings Flash (TNGX) Tango Therapeutics Posts Q2 Loss $0.37 a Share, Vs. FactSet Est of $0.32 Loss - moomoo.com
TNGX Q2'26 Earnings: EPS estimate is (0.32) USD - TradingView
Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights - Yahoo Finance
TNGX Stock Hits All-Time High – Wolfe Research Calls Tango Therapeutic’s Pancreatic Cancer Trial Data ‘Groundbreaking’ - Stocktwits
345,156 Shares in Tango Therapeutics, Inc. $TNGX Acquired by Assenagon Asset Management S.A. - MarketBeat
Tango Therapeutics (TNGX) Earnings Date and Reports 2026 - MarketBeat
The Manufacturers Life Insurance Company Boosts Holdings in Tango Therapeutics, Inc. $TNGX - MarketBeat
Certain Stock Options of Tango Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 8-AUG-2026. - marketscreener.com
Tango Therapeutics Announces Executive Chair Barbara Weber’s Departure - theglobeandmail.com
Tango Therapeutics (NASDAQ:TNGX) Trading Down 6.1%What's Next? - MarketBeat
Form 8K Tango Therapeutics Inc For: 7 August By Investing.com - Investing.com South Africa
Tango Therapeutics (NASDAQ: TNGX) outlines Barbara Weber separation package - Stock Titan
Form 8K Tango Therapeutics Inc For: 6 August By Investing.com - Investing.com South Africa
Tango Therapeutics Announces Executive Chair Transition - sahmcapital.com
Tango Therapeutics Inc (TNGX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.52%
0.07%
자본화:
|
볼륨(24시간):